IMNM · Insider Trading
Immunome, Inc.
Every open-market purchase and sale reported by IMNM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Jack Higgins | Chief Scientific Officer | MIXED | −4,000 | −$309.92K |
| 2026-08-12 | Isaac Barchas | Director | Sell | −83,464 | −$2.20M |
| 2026-08-10 | Isaac Barchas | Director | Sell | −36,088 | −$940.45K |
| 2026-08-06 | Kinney Horn | CHIEF BUSINESS OFFICER | MIXED | — | −$1.20M |
| 2026-07-27 | Max Rosett | Chief Financial Officer | A | +47,250 | — |
| 2026-07-27 | Philip Tsai | Chief Technical Officer | A | +38,250 | — |
| 2026-07-27 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | A | +38,250 | — |
| 2026-07-27 | Clay B Siegall | President and CEO | A | +180,000 | — |
| 2026-07-27 | Kinney Horn | CHIEF BUSINESS OFFICER | A | +31,250 | — |
| 2026-07-27 | Robert Lechleider | Chief Medical Officer | A | +54,000 | — |
| 2026-07-27 | Jack Higgins | Chief Scientific Officer | A | +38,250 | — |
| 2026-07-09 | Kinney Horn | CHIEF BUSINESS OFFICER | MIXED | — | −$13.19K |
| 2026-07-07 | Robert Lechleider | Chief Medical Officer | MIXED | — | −$764.18K |
| 2026-07-07 | Isaac Barchas | Director | Sell | −100,000 | −$2.41M |
| 2026-07-02 | Isaac Barchas | Director | Sell | −201,050 | −$4.39M |
| 2026-06-29 | Robert Lechleider | Chief Medical Officer | MIXED | — | −$611.51K |
| 2026-06-17 | Max Rosett | Chief Financial Officer | MIXED | — | −$1.03M |
| 2026-06-12 | Sandra M Swain | Director | A | +9,897 deriv. | — |
| 2026-06-12 | Isaac Barchas | Director | A | +9,897 deriv. | — |
| 2026-06-12 | Jean Jacques Bienaime | Director | A | +9,897 deriv. | — |
| 2026-06-12 | James P Boylan | Director | A | +9,897 deriv. | — |
| 2026-06-12 | Philip Wagenheim | Director | A | +9,897 deriv. | — |
| 2026-06-12 | Carol Schafer | Director | A | +9,897 deriv. | — |
| 2026-06-09 | Jean Jacques Bienaime | Director | MIXED | — | +$440 |
| 2026-05-19 | Jean Jacques Bienaime | Director | Buy | +5,000 | +$103.50K |
| 2026-04-03 | Jack Higgins | Chief Scientific Officer | Sell | −9,438 | −$204.24K |
| 2026-04-03 | Max Rosett | Chief Financial Officer | MIXED | +6,561 | −$1.34M |
| 2026-04-01 | Jack Higgins | Chief Scientific Officer | G | −6,291 | — |
| 2026-03-23 | Philip Wagenheim | Director | Sell | −65,000 | −$1.34M |
| 2026-03-12 | Jean Jacques Bienaime | Director | Buy | +2,000 | +$43.67K |
| 2025-12-30 | Clay B Siegall | President and CEO | Buy | +4,729 | +$100.02K |
| 2025-12-23 | Isaac Barchas | Director | Sell | −383,200 | −$8.33M |
| 2025-12-22 | Philip Tsai | Chief Technical Officer | Buy | +10,000 | +$204.90K |
| 2025-12-22 | Clay B Siegall | President and CEO | MIXED | −192,722 | +$149.05K |
| 2025-12-22 | Jack Higgins | Chief Scientific Officer | G | — | — |
| 2025-12-18 | Clay B Siegall | President and CEO | Buy | +46,511 | +$999.99K |
| 2025-09-11 | Jack Higgins | Chief Scientific Officer | M | +22,000 | +$29.70K |
| 2025-07-31 | Clay B Siegall | President and CEO | A | +800,000 deriv. | — |
| 2025-07-31 | Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | A | +190,000 deriv. | — |
| 2025-07-31 | Max Rosett | Chief Financial Officer | A | +207,000 deriv. | — |
| 2025-07-31 | Robert Lechleider | Chief Medical Officer | A | +242,000 deriv. | — |
| 2025-07-31 | Philip Tsai | Chief Technical Officer | A | +190,000 deriv. | — |
| 2025-07-31 | Kinney Horn | CHIEF BUSINESS OFFICER | A | +161,000 deriv. | — |
| 2025-07-31 | Jack Higgins | Chief Scientific Officer | A | +196,000 deriv. | — |
| 2025-06-12 | Jean Jacques Bienaime | Director | A | +18,864 deriv. | — |
| 2025-06-12 | Carol Schafer | Director | A | +18,864 deriv. | — |
| 2025-06-12 | Isaac Barchas | Director | A | +18,864 deriv. | — |
| 2025-06-12 | James P Boylan | Director | A | +18,864 deriv. | — |
| 2025-06-12 | Sandra M Swain | Director | A | +18,864 deriv. | — |
| 2025-06-12 | Philip Wagenheim | Director | A | +18,864 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Clay B Siegall | President and CEO | 870,704 | $16.24M |
| Philip Wagenheim | Director | 341,147 | $6.36M |
| Isaac Barchas | Director | 154,502 | $2.88M |
| Max Rosett | Chief Financial Officer | 101,287 | $1.89M |
| Kinney Horn | CHIEF BUSINESS OFFICER | 90,616 | $1.69M |
| Philip Tsai | Chief Technical Officer | 81,550 | $1.52M |
| Robert Lechleider | Chief Medical Officer | 69,805 | $1.30M |
| Jack Higgins | Chief Scientific Officer | 66,050 | $1.23M |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 43,805 | $816.96K |
| Jean Jacques Bienaime | Director | 38,915 | $725.76K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMNM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.